Pain relief and quality‐of‐life assessment following intravenous and oral clodronate in hormone‐escaped metastatic prostate cancer
Authors:
- 1 September 1995
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 76 (3) , 360-365
Abstract
Objective To establish the efficacy of intravenous clodronate followed by maintenance oral clodronate in patients with painful bone metastases resulting from hormone‐resistant prostate cancer. Patients and methods A multicentre open study of 27 patients assessed the efficacy of clodronate treatment by estimating the reduction in World Health Organization (WHO) Pain Score, the increase in WHO Performance Status and by a novel quality‐of‐life/ activity score. Results Ten of 27 patients achieved significant pain relief after receiving 300 mg/day of intravenous clodronate for 10 days. This was matched by an improvement in the activity score and WHO Performance Status. Three of 27 patients continued to have relief from pain after 3 months of oral clodronate therapy. Conclusion Intravenous clodronate therapy was effective in relieving the pain resulting from prostate cancer bone metastases in 10 of 27 patients but the benefit was shortlived. The use of a personal quality‐of‐life/ activity questionnaire which assesses aspects of everyday life that are important to the patient may be more appropriate for patients with very advanced prostate cancer than are other quality‐of‐life questionnaires in current use.Keywords
This publication has 13 references indexed in Scilit:
- The use of bisphosphonates in prostatic cancerClinical Oncology, 1994
- Biphosphonates as an Adjunct to Palliative Therapy of Bone Metastases from Prostatic Carcinoma. A Pilot Study on ClodronateBritish Journal of Urology, 1993
- Effect of oral clodronate on bone painInternational Urology and Nephrology, 1992
- Quality of life and treatment of hormone resistant metastatic prostatic cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Clodronate Therapy of Metastatic Bone Disease in Patients with Prostatic Carcinoma1989
- Bisphosphonates and bone metastasesBritish Journal of Cancer, 1988
- Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.Journal of Clinical Oncology, 1988
- Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancyBMJ, 1988
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBritish Journal of Urology, 1985
- Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorptionPostgraduate Medical Journal, 1985